Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial ResultsUnusual Whales·Aug 20 at 07:12 PM02137-0.49%
Brii Biosciences: Loss narrowed 32% to RMB101M as HBV and RNA pipelines advanced; cash at RMB1.77BQuartr·Aug 20 at 06:09 PM02137-0.49%
Tech M&A and Capital Restructuring Define Early 2026 Moves Across Hong Kong EquitiesGlobal Report·Aug 11 at 04:43 AM02533-4.77%02137-0.49%
Beyond the Tech Giants: The Hidden Middle Class of HKEX in 2026Global Report·Aug 5 at 04:13 AM01066-1.29%01361-3.46%
Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studiesWorldPharmaceuticals·Jul 6 at 05:35 AM02137-0.49%
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis BPR Newswire·Jul 2 at 07:00 PM02137-0.49%VIR+6.19%
Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by ArbitrationTip Ranks·Jul 2 at 06:07 PM02137-0.49%
Brii Biosciences says arbitration with Vir clouds future of elebsiran programPUBT·Jul 2 at 05:56 PM02137-0.49%VIR+6.19%
Brii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock ValueTip Ranks·Jun 17 at 09:09 AM02137-0.49%
Brii Biosciences and OpenBench collaborate for tech platform. Durham, Beijing, and San Francisco, Dec. 11, 2025.Unusual Whales·Dec 11, 2025 at 06:32 AM02137-0.49%
